Payment overview · 2025
General Payments
$1,473.98
81 reported records · 24 companies
Healthcare provider profile · identity verified
Ruby Renee Leach, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LEXINGTON, KY · NPI 1376637942
Verified facts
What the public records show
CMS Open Payments records show Ruby Renee Leach, APRN received $1,473.98 in general payments during 2025 across 81 reported records.
ABBVIE INC. accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.84 | 13.8% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.66 | 12.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $177.57 | 12.1% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $93.41 | 6.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $88.34 | 6.0% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.95 | 5.6% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $74.62 | 5.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.11 | 5.0% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $55.35 | 3.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.05 | 3.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.65 | 3.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.23 | 3.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.97 | 2.6% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $34.84 | 2.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.94 | 2.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.44 | 2.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.27 | 1.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.09 | 1.6% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $20.41 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.22 | 1.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.15 | 1.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.01 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.06 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.80 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,473.98 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $164.62 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $160.46 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $139.49 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $126.80 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.47 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $81.95 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.43 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $74.62 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $59.53 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.00 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.05 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.67 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $45.23 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.44 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.27 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| ELAPRASE Normalized: elaprase |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $11.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 51 |
| Lisinopril | Lisinopril | 193 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 58 |
| Omeprazole | Omeprazole | 144 | 47 |
| Montelukast Sodium | Montelukast Sodium | 122 | 33 |
| Losartan Potassium | Losartan Potassium | 121 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 26 |
| Famotidine | Famotidine | 83 | 22 |
| Simvastatin | Simvastatin | 81 | 24 |
| Trazodone Hcl | Trazodone Hcl | 79 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 25 |
| Potassium Chloride | Potassium Chloride | 67 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 16 |
| Metformin Hcl | Metformin Hcl | 58 | 18 |
| Metformin Hcl Er | Metformin Hcl | 58 | 18 |
| Allopurinol | Allopurinol | 55 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 14 |
| Ozempic | Semaglutide | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 20 |
| Methylprednisolone | Methylprednisolone | 43 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | 12 |
| Synthroid | Levothyroxine Sodium | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 13 |
| Furosemide | Furosemide | 35 | 16 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Gabapentin | Gabapentin | 32 | 13 |
| Bupropion Xl | Bupropion Hcl | 30 | 12 |
| Carvedilol | Carvedilol | 30 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Atenolol | Atenolol | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,473.98 · 81 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BEXSERO, BREZTRI, CAPLYTA, CAPVAXIVE, Dyanavel XR, EDARBI, ELAPRASE, EVENITY, FANAPT, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, M-M-R II, MOUNJARO, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TEZSPIRE, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, XYOSTED, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error